BioCentury
ARTICLE | Clinical News

Novartis' canakinumab reduces CV risk in CANTOS subgroup

January 5, 2018 9:48 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from a subgroup of patients who achieved a high sensitivity C-reactive protein (hsCRP) level of <2 mg/L at three months after the first dose of subcutaneous canakinumab (ACZ885) in the Phase III CANTOS cardiovascular (CV) outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis. In the subgroup, canakinumab reduced the risk of major cardiovascular adverse events (MACE) by 25% vs. placebo (p<0.0001). Compared to placebo, canakinumab also significantly reduced the incidence of CV death and all-cause mortality by 31% in the subgroup (p=0.0004 and p<0.0001, respectively).

The pharma said the data suggest that hsCRP testing at three months after the first dose of canakinumab could be a reliable way to identify the patients most likely to achieve the greatest benefit from continued treatment with canakinumab. Data were presented at the American Heart Association meeting in Chicago in November and published in The Lancet...

BCIQ Company Profiles

Novartis AG

BCIQ Target Profiles

Interleukin-1 (IL-1) beta